Literature DB >> 12382231

The Acute Dialysis Quality Initiative--part VI: access and anticoagulation in CRRT.

Andrew Davenport1, Sangeeta Mehta.   

Abstract

Both the choice of vascular access and anticoagulant regimen for continuous renal replacement therapy (CRRT) are a major determinant of not only circuit life span but also affect solute clearance. This evidence-based review critically examines the published rature on different vascular access sites, access types, and anticoagulation regimens, to provide clinical guidelines for good working practices and to direct future studies. Copyright 2002 by the National Kidney Foundation, Inc.

Mesh:

Substances:

Year:  2002        PMID: 12382231     DOI: 10.1053/jarr.2002.35566

Source DB:  PubMed          Journal:  Adv Ren Replace Ther        ISSN: 1073-4449


  4 in total

Review 1.  Anticoagulation strategies in continuous renal replacement therapy: can the choice be evidence based?

Authors:  H M Oudemans-van Straaten; J P J Wester; A C J M de Pont; M R C Schetz
Journal:  Intensive Care Med       Date:  2006-02-02       Impact factor: 17.440

Review 2.  What are the anticoagulation options for intermittent hemodialysis?

Authors:  Andrew Davenport
Journal:  Nat Rev Nephrol       Date:  2011-07-05       Impact factor: 28.314

3.  Blood flow reductions during continuous renal replacement therapy and circuit life.

Authors:  Ian Baldwin; Rinaldo Bellomo; Bill Koch
Journal:  Intensive Care Med       Date:  2004-09-24       Impact factor: 17.440

4.  Citrate anticoagulation for continuous renal replacement therapy (CRRT) in patients with acute kidney injury admitted to the intensive care unit.

Authors:  Andrew Davenport; Ashita Tolwani
Journal:  NDT Plus       Date:  2009-09-25
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.